SILVERPATH INC. NPI 1750944526

NPI Details

SILVERPATH, INC. is a clinical medical laboratory in Blue Bell, PA. The provider is (1) A clinical laboratory is a facility for the biological, microbiological, serological, chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, human beings. These examinations also include procedures to determine, measure, or otherwise describe the presence or absence of various substances or organisms in the body. Facilities only collecting or preparing specimens (or both) or only serving as a mailing service and not performing testing are not considered clinical laboratories. (2) Any facility that examines materials from the human body for purposes of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of, the health of human beings. Typical divisions of a clinical laboratory include hematology, cytology, bacteriology, histology, biochemistry, medical toxicology, and serology. SILVERPATH, INC. NPI is 1750944526. The provider is registered as an organization entity type and is a multi-specialty group.
The provider Is Doing Business As Korgene.

The provider's business location address is:

512 E. TOWNSHIP LINE ROAD
SUITE 135, TOWER 4
BLUE BELL, PA
ZIP 19422-700
Phone: (854) 429-1069
Fax: (833) 247-4091

The provider's authorized official is Shea Harrelson .
The authorized official title is Ceo/co-owner and has the following contact phone number (854) 429-1069.

The CLIA number assigned to this NPI record is 39D2166771 - independent with a certificate type of Certificate of Accreditation.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Detection test by nucleic acid for organism, amplified probe technique (HCPCS:87798)
• Detection test for candida species (yeast), amplified probe technique (HCPCS:87481)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r (HCPCS:U0003)
• Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique (HCPCS:87641)
• Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique (HCPCS:87500)
• Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within (HCPCS:U0005)
• Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique (HCPCS:87653)
• Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique (HCPCS:87640)
• Detection test by nucleic acid for herpes simplex virus, amplified probe technique (HCPCS:87529)
• Detection test for gardnerella vaginalis (bacteria), amplified probe technique (HCPCS:87511)
• Detection of mycoplasma genitalium by dna or rna probe (HCPCS:87563)
• Detection test by nucleic acid for human papillomavirus (hpv), types 16 and 18 only (HCPCS:87625)
• Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique (HCPCS:87591)
• Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique (HCPCS:87491)
• Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique (HCPCS:87661)
• Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique (HCPCS:87651)
• Detection test by nucleic acid for clostridium difficile, amplified probe technique (HCPCS:87493)
• Detection test by nucleic acid for mycobacteria tuberculosis (tb bacteria), amplified probe technique (HCPCS:87556)
• Detection by nucleic acid bartonella henselae and bartonella quintana (bacteria), amplified probe technique (HCPCS:87471)
• Detection test by nucleic acid for legionella pneumophila (water borne bacteria), amplified probe technique (HCPCS:87541)
• Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique (HCPCS:87581)
• Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique (HCPCS:87486)
• Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source (HCPCS:G2023)
• Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets (HCPCS:87631)
• Detection test by nucleic acid for digestive tract pathogen, multiple types or subtypes, 6-11 targets (HCPCS:87506)
• Detection test by nucleic acid for digestive tract pathogen, multiple types or subtypes, 3-5 targets (HCPCS:87505)
• Measurement of dna of bacteria in vaginal fluid specimen (HCPCS:81514)
• Gene analysis (cytochrome p450, family 2, subfamily d, polypeptide 6) common variants (HCPCS:81226)
• Gene analysis (cytochrome p450, family 2, subfamily c, polypeptide 19) common variants (HCPCS:81225)
• Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source (HCPCS:G2023)
• Measure of severe acute respiratory syndrome coronavirus 2 (covid-19) antibody (HCPCS:86769)
• Detection test by nucleic acid for digestive tract pathogen, multiple types or subtypes, 12-25 targets (HCPCS:87507)

The enumeration date for this NPI number is 4/17/2019 and was last updated on 10/4/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: